Professional Documents
Culture Documents
at ESC Congress 2018
This Satellite Symposium is organized and funded by Novartis Pharma AG
© 2018 Novartis Pharma AG, CH-4002 Basel
August 2018, GLCM/HTF/0572
Professor Burkert Pieske
Director of the Department of Internal Medicine and Cardiology
at Charité University Medicine Berlin–Campus Virchow Klinikum
and Department of Internal Medicine and Cardiology, German
Heart Institute Berlin, in Germany
Disclosures
• Lecture, Advisory Board, and EC membership fees from Bayer
Healthcare, Novartis, MSD, Stealth Peptides, Servier, Astra-
Zeneca, Daiichi-Sankyo, WebMed
Seize the moment to optimize treatment for each
patient with heart failure: why, when, and how
Chairs: John McMurray (United Kingdom) and Burkert Pieske (Germany)
13:00–13:03 Welcome and introduction
Burkert Pieske (Germany)
13:03–13:18 What action should we take when we see patients with perceived stable heart failure?
John McMurray (United Kingdom)
13:18–13:33 Hospital admission for heart failure: an opportunity to optimize heart failure therapy?
Rolf Wachter (Germany)
13:33–13:48 Living with heart failure: what do patients care about?
Scott Solomon (United States)
13:48–13:58 Panel discussion and audience Q&A
Moderator: Burkert Pieske (Germany)
Panel: John McMurray (United Kingdom), Rolf Wachter (Germany), Scott Solomon (United States)
This Satellite Symposium is organized and funded by Novartis Pharma AG
© 2018 Novartis Pharma AG, CH-4002 Basel
August 2018, GLCM/HTF/0572
Participate in voting Live Q&A
1. Select Voting 2. Tap the number 1. Select Q&A 2. Write your question
corresponding - tap Send
to your vote
This Satellite Symposium is organized and funded by Novartis Pharma AG
© 2018 Novartis Pharma AG, CH-4002 Basel
August 2018, GLCM/HTF/0572
Join us for…
Satellite Symposium –
Experts on the Spot
Seize the moment to optimize heart failure
treatment: why, when, and how? Ask the experts
16:00–16:30, Haendel – The Hub
This Satellite Symposium is organized and funded by Novartis Pharma AG
© 2018 Novartis Pharma AG, CH-4002 Basel
August 2018, GLCM/HTF/0572